SIGA Technologies
institution
A company whose main product is a smallpox drug for a disease that was eradicated in 1980.
Who they are
SIGA Technologies, alongside Emergent a main beneficiary of biodefense procurement[1].
What they do
The engine treats it as a second instance of the same pattern.
How it works
Its principal asset is TPOXX (tecovirimat), a smallpox antiviral.
Why it matters
Kept deliberately thin here: the wider claims about its contract history were dropped during checking because the sources cited did not carry them. What remains is what the SEC filings support.
The engine's record — word for word
SIGA Technologies is a specialized biopharmaceutical entity that operates alongside Emergent BioSolutions as a primary beneficiary of the U.S. biodefense procurement monopoly.[1] SIGA's primary asset is TPOXX (tecovirimat), a smallpox antiviral therapeutic.[2] SIGA's own annual report states that oral TPOXX is not approved for sale in the United States beyond sales to the U.S. government for stockpiling, that the market for sales to customers other than the U.S. government is undeveloped, and that the success of the business for the foreseeable future will be substantially dependent on the U.S. government's commitment to maintaining or expanding its stockpile.[3] The same filing records that the BARDA contract is primarily option-based, with more than 80% of contract value tied to options exercisable in BARDA's sole discretion.[4]
Follow the trail
Walk this on the live map →